Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance

Br J Dermatol. 2023 Nov 16;189(6):767-769. doi: 10.1093/bjd/ljad279.

Authors

Bianca Bergamini¹, Julien Seneschal², Kristin J Meyers¹, Frederick Durand¹, Ewa Haladyj¹, Gerard Espinosa³, Jacob P Thyssen⁴

Affiliations

¹ Eli Lilly and Company, Indianapolis, IN, USA.
² Department of Dermatology, National Reference Center for Rare Skin Disorders, CNRS, UMR5164, ImmunoConCept, University of Bordeaux, Bordeaux, France.
³ Department of Autoimmune Diseases, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia,Spain.
⁴ Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.

PMID: 37595142
DOI: 10.1093/bjd/ljad279

No abstract available

MeSH terms

Azetidines* / adverse effects
Clinical Trials as Topic
Female
Humans
Pregnancy
Pregnancy Outcome*
Product Surveillance, Postmarketing
Purines / adverse effects

Substances

Azetidines
baricitinib
Purines

Grants and funding

Eli Lilly and Company